Anais brasileiros de dermatologia · 2025
Efficacy and safety of nemolizumab in prurigo nodularis: a systematic review and meta-analysis of randomized controlled trials.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vieira Ana Carolina Putini, Cruz Akabane Maria Antônia Costa, Caletti Gianna Carolinne Graff, Heffel Kélen Klein, Tauana Oliveira E Silva Amanda
Аннотация
BACKGROUND: Prurigo nodularis (PN) is a chronic, debilitating inflammatory skin disorder characterized by persistent itching, firm pruritic nodular lesions, and evidence of frequent scratching, like excoriation, and lichenification. Nemolizumab, a monoclonal antibody targeting IL-31, has shown significant improvements in skin lesions, itching, and sleep disturbances by reducing type 2 immune responses in PN.
OBJECTIVES: Evaluate the efficacy and safety of nemolizumab in treating PN by systematically analyzing randomized controlled trials (RCTs).
METHODS: The authors conducted a systematic review and meta-analysis by searching Pubmed, Embase, Cochrane Central and Scopus for RCTs comparing nemolizumab to placebo for PN. Statistical analysis usedR Studio 4.3.2.
RESULTS: Three trials, involving 630 patients, were included. Nemolizumab significantly reduced pruritus at week-4 (MD = -32.04; 95% CI: -38.47, -25.62) and at week-16 (MD = -347.34; 95% CI: -1039.71, 345.04). Investigator's Global Assessment (IGA) success favored Nemolizumab at week-16 (RR = 3.50; 95% CI: 2.18, 5.63). No significant differences were observed in adverse events (RR = 1.10; 95% CI: 0.97, 1.25) or serious adverse events (RR = 0.77; 95% CI: 0.43, 1.39). Nemolizumab also significantly reduced neurodermatitis.
STUDY LIMITATIONS: Limitations include variability in treatment duration, small sample sizes, and the lack of direct comparisons with other biologics.
CONCLUSION: Our meta-analysis shows that Nemolizumab significantly improves pruritus, IGA success rates, and PAS > 75% in treating patients with moderate to severe PN. Its safety profile is favorable, with no significant differences in adverse events compared to placebo. These findings support Nemolizumab as a viable treatment for moderate to severe PN.
OBJECTIVES: Evaluate the efficacy and safety of nemolizumab in treating PN by systematically analyzing randomized controlled trials (RCTs).
METHODS: The authors conducted a systematic review and meta-analysis by searching Pubmed, Embase, Cochrane Central and Scopus for RCTs comparing nemolizumab to placebo for PN. Statistical analysis usedR Studio 4.3.2.
RESULTS: Three trials, involving 630 patients, were included. Nemolizumab significantly reduced pruritus at week-4 (MD = -32.04; 95% CI: -38.47, -25.62) and at week-16 (MD = -347.34; 95% CI: -1039.71, 345.04). Investigator's Global Assessment (IGA) success favored Nemolizumab at week-16 (RR = 3.50; 95% CI: 2.18, 5.63). No significant differences were observed in adverse events (RR = 1.10; 95% CI: 0.97, 1.25) or serious adverse events (RR = 0.77; 95% CI: 0.43, 1.39). Nemolizumab also significantly reduced neurodermatitis.
STUDY LIMITATIONS: Limitations include variability in treatment duration, small sample sizes, and the lack of direct comparisons with other biologics.
CONCLUSION: Our meta-analysis shows that Nemolizumab significantly improves pruritus, IGA success rates, and PAS > 75% in treating patients with moderate to severe PN. Its safety profile is favorable, with no significant differences in adverse events compared to placebo. These findings support Nemolizumab as a viable treatment for moderate to severe PN.